Tango Therapeutics (TNGX) Revenue (2020 - 2025)

Tango Therapeutics' Revenue history runs 6 years deep, the most recent figure standing at $53.8 million for Q3 2025.

• In Q3 2025, Revenue rose 363.61% year-over-year to $53.8 million; the TTM figure through Mar 2026 stood at $57.0 million (up 39.04% YoY), while the FY2025 annual figure was $62.4 million, up 48.29% from the prior year.
• Revenue for Q3 2025 stood at $53.8 million, up from $3.2 million in the prior quarter.
• The five-year high for Revenue was $53.8 million in Q3 2025, with the low at $3.2 million in Q2 2025.
• The 5-year median for Revenue is $6.4 million (2022), against an average of $10.7 million.
• Peak annual rise in Revenue reached 363.61% in 2025, while the deepest fall reached 83.99% in 2025.
• Tango Therapeutics' Revenue stood at $5.7 million in 2021, then increased by 12.16% to $6.4 million in 2022, then dropped by 15.29% to $5.4 million in 2023, then retreated by 24.19% to $4.1 million in 2024, then surged by 1207.04% to $53.8 million in 2025.
• Business Quant data shows TNGX's Revenue at $53.8 million in Q3 2025, $3.2 million in Q2 2025, and $5.4 million in Q1 2025.